Briumvi (ublituximab-xiiy)

Briumvi (ublituximab-xiiy) is a cellular cytolytic that binds to the CD20 on the surface of the B Lympochites indicated for the treatment of Multiple Sclerosis (MS).

Briumvi (ublituximab-xiiy) was approved by the FDA in December 2022.

  • Disease Indications : Multiple Sclerosis
  • Manufacturer: TG Therapeutics
  • Usage : Intravenous
Medicine approved by
  • European Medical Agency (EMA)
  • Food and Drug Administration (FDA)